Zhang J et al. constructed a predictive model including PDE2A and the other six genes, successfully predicting the survival rate of cholangiocarcinoma, HCC, and pancreatic adenocarcinoma patients [15]. This evidence concerns the gene PDE2A and hepatocellular carcinoma.